Industry

Industry — Insurance: Life & Multi-line

1. Industry in One Page

Life and multi-line insurance is a spread business with a long tail and a balance sheet 25× the size of equity. Customers pay premiums today; the insurer promises a payment far in the future (death benefit, annuity income, disability claim) and earns the gap between (a) what it invests the float at and (b) what it owes plus the cost of running the business. Globally, life premiums totaled roughly $3.1 trillion in 2024 and are forecast to reach $4.8 trillion by 2035, with 2025-2026 real growth of about 3% per year — more than double the 1.4% pace of the prior decade — driven by higher interest rates, ageing baby boomers, and a growing middle class in emerging markets (Swiss Re sigma).

The most common newcomer mistake is treating these companies as "insurance" when the dominant earnings driver for a U.S. life insurer is investment spread on the general-account portfolio, not premium-vs-claim underwriting. Margins are thin in revenue terms (MET's 4.4% net margin) because most of "revenue" is policyholder money that flows back out as benefits — what matters is return on equity at a leveraged book.

Takeaway: The economics live in stage 3, not stage 1. Premium "revenue" is a gross flow; the spread on invested float is the profit engine.

2. How This Industry Makes Money

A life insurer earns three streams: investment spread, underwriting margin, and fee income. The mix decides how the company behaves through cycles.

• Investment spread (the biggest piece for U.S. life and annuity): insurer collects, say, 5.5% on its bond/loan/private-credit portfolio and credits 3.5% to policyholders, retaining the ~200 bp gap on ~$500B+ of general-account assets at large players. This is why every life-insurer earnings call leads with "net investment income," "yield on new money," and "core spread." It is also why life insurers are essentially levered fixed-income managers with regulatory and actuarial constraints.
• Underwriting margin: pricing premiums above expected mortality, morbidity (disability/health), and longevity. Group benefits (term life, dental, disability) reprice annually; individual life prices for decades.
• Fee income: asset management (e.g., MetLife Investment Management at ~$736B Total AUM), administrative services-only contracts, separate-account fees on variable products. Capital-light and trades at higher multiples — which is why MIM's $200M of FY2025 adjusted earnings carries strategic weight disproportionate to its scale.

Cost structure is largely fixed. The big lines are claims (variable but slow-moving and pre-priced), interest credited to policyholders (locked in by contract), distribution costs, technology/operations, and regulatory overhead. Claims are not "controllable" each quarter — they are priced years in advance, so margin compression typically comes from investment underperformance, longevity surprises, or aggressive competitor pricing, not cost overruns.

Capital is the binding constraint. U.S. life insurers operate to a Risk-Based Capital ratio (RBC), with regulators setting "company action level" thresholds. MET reports a Statement-Based Combined RBC ratio above 350%. Asset leverage runs roughly 25-30× equity, so a 1% impairment on the bond book can wipe a quarter of book value.

Bargaining power is split. Group buyers (large employers) and pension plan sponsors have meaningful pricing power; individual retail customers have very little. Distribution intermediaries (banks, broker-dealers, benefit consultants like Aon and Mercer) extract significant economics — MET's 10-K explicitly flags that "bank, broker-dealer and asset manager consolidation could increase competition for access to distributors."

3. Demand, Supply, and the Cycle

Demand drivers are demographic and macro, not cyclical in the GDP sense. Three forces matter most:

1. Interest rates. Higher rates raise the spread on new asset purchases, lift discount rates on reserves (releasing capital), and make fixed annuities and pension risk transfer (PRT) economically attractive. The 2022-2025 rate cycle drove record U.S. annuity sales (over $400B in 2024 vs a 10-year average of $234B per Swiss Re/LIMRA).
2. Demographics. Baby boomers retiring → annuity and PRT demand. Asia and LatAm middle-class formation → individual life/savings demand. Aging workforces → group disability and supplemental health utilization.
3. Employer behavior + labor markets. Group benefits demand tracks employment levels and the breadth of benefits employers offer. Voluntary/worksite products grow faster than core group when employers shift cost to employees.

Supply (capacity) is constrained by capital and regulator solvency rules. Unlike P&C, supply rarely "shocks" downward — it deteriorates slowly through credit losses, longevity revisions, or balance-sheet de-risking when reserves prove inadequate.

Where the cycle hits first: investment income and annuity flows, then reserves. A 2008-style rate-and-credit shock hits in three waves: (1) immediate mark-to-market and impairment losses; (2) fee and spread compression as new money is invested at lower rates; (3) reserve strengthening if the assumption set proves wrong. MetLife's FY2009 result — a $2.4B net loss versus a $4.2B profit in FY2007 — is the canonical illustration; full GAAP earnings recovery took until FY2011, and the variable-annuity book that built up before 2008 became the run-off "MetLife Holdings" segment that the company is still working down today.

4. Competitive Structure

The U.S. life industry is moderately fragmented, with the largest players being mutuals — not stock companies. Northwestern Mutual, MassMutual, and New York Life lead the U.S. market in direct life premiums; large stock peers like MetLife, Prudential, and Corebridge follow. MET's "share" of U.S. life is structurally capped because mutuals — accountable to policyholders, not shareholders — can underprice for share without an ROE constraint.

The competitive landscape segments by product, not by single national share:

• Group benefits (U.S.): oligopolistic at the top of the market. MET, Cigna/New York Life, Unum, Lincoln, Guardian, The Hartford, Sun Life. Annual repricing creates ongoing churn.
• Pension risk transfer (U.S.): highly concentrated. Prudential and MetLife are the dominant historical providers, with Athene, Legal & General America, Massachusetts Mutual, and a handful of others bidding on jumbo deals. Capacity is regulator- and capital-constrained, which makes it returns-rich for incumbents with scale.
• Individual life and annuity (U.S.): fragmented and increasingly contested by PE-backed platforms — Athene/Apollo, Brookfield Reinsurance, Global Atlantic/KKR, Resolution Life — that fund growth with reinsurance and alternative-credit yield. Spreads on retail annuity issuance have compressed.
• Asia (Japan, Korea): dominated by domestic giants (Nippon Life, Dai-ichi, Meiji Yasuda; Samsung Life, Hanwha) plus AIA, Allianz, Manulife and select foreign incumbents like MetLife.
• Asset management (institutional fixed income, private credit): hyper-competitive; competing with PIMCO, BlackRock, Apollo, Blackstone, KKR, and most large-bank-affiliated managers.

FY2025 figures. Note the wide margin range: AFL (21%) is mostly capital-light supplemental underwriting; MET (4%) is spread + scale + ASO. The two business models are barely comparable on margin alone.

The right metric is ROE, not net margin. AFL writes far less general-account business and runs at lower asset leverage. MET's economic engine is leverage on a much larger float — and on ROE, the public peer set clusters in a 7-13% band.

5. Regulation, Technology, and Rules of the Game

This is one of the most regulated industries in financial services. Capital adequacy, reserve methodology, product approval, market conduct, and even cybersecurity are governed jurisdiction-by-jurisdiction — and a single change can move billions of statutory capital. The investor must read three regulators at once for a global player like MET: NAIC (U.S. states, with NYDFS as MET's lead), Solvency II (EEA + UK), and Asia local regimes (FSA Japan, FSS Korea, NFRA China).

Technology shifts that change economics, not just operations:

• Underwriting AI / accelerated underwriting: cuts per-policy issue cost by ~40-60% on individual life, expanding the addressable middle market for term life. Favors carriers with scale data sets.
• PE-platform reinsurance arbitrage: alternative-credit asset sourcing (private credit, structured products, CMBS) lets non-traditional buyers offer higher crediting rates on annuities, structurally compressing public-life spreads.
• Embedded insurance: distribution shift to digital-platform partners (banks, employee-benefits portals, fintech apps). Disintermediates traditional agency for simple products; favors brand and infrastructure scale.
• IFRS 17 / new accounting: changes how international peers report earnings (effective 2023). Makes cross-border peer comparison harder for non-U.S. insurers.

6. The Metrics Professionals Watch

Generic financial ratios mislead in this industry. The 7 metrics below explain how value is created or lost.

7. Where MetLife, Inc. Fits

MetLife is the scale-diversified incumbent in U.S. group benefits and U.S. pension risk transfer, with a uniquely broad international franchise (Asia + LatAm + EMEA) plus a $736B Total AUM institutional asset manager (Q1 2026 disclosure). It is one of three remaining U.S.-listed life insurers above $50B market cap (alongside AFL and PRU); the largest U.S. life books — Northwestern Mutual, MassMutual, NY Life — are mutuals and not investable.

The FY2025 segment earnings mix tells the most important positioning story: adjusted earnings are roughly balanced across Group Benefits, RIS, and Asia, with LatAm + EMEA + MIM rounding out the portfolio. No single segment generates more than 30% of group earnings, which makes MET more diversified than PRU (Japan + PGIM heavy), AFL (Japan + supplemental), or pure-play U.S. peers.

MET is not a pure-play. Its earnings power is the sum of three different business models — group benefits underwriter, spread-and-scale retirement-solutions provider, and Asia growth + asset-management leg. The investment thesis turns on management's ability to keep all three in motion under the New Frontier 2026-2029 plan.

8. What to Watch First

Five-to-seven signals that flip the industry backdrop for MET, observable within a quarter:

1. U.S. 10-year Treasury and IG corporate spread. A 50+ bp move in either direction will show up first in MET's new-money yield commentary on the next call. Falling rates compress RIS spreads; widening spreads stress mark-to-market on the bond book and the alt-investment line.
2. Pension Risk Transfer pipeline disclosure (LIMRA quarterly + earnings supplements). Industry PRT volume tracks the funded status of corporate DB plans. A material drop signals weakening demand for MET's RIS; jumbo-deal participation signals share movement vs Prudential.
3. Group Benefits sales and persistency in the spring renewal cycle. Most contracts renew Jan-Apr. Sales growth above mid-single-digits and persistency above 90% confirm pricing power. Watch the Q2 earnings deck.
4. Adjusted ROE relative to the 13-15% New Frontier target. Anything sustained below 12% raises questions about capital deployment; anything above 15% is unusual and likely indicates either favorable assumption updates or underinvestment.
5. MIM net inflows + AUM trajectory toward $1T. PineBridge integration (closed Dec 30, 2025) lifted Total AUM by 22% YoY to $736B at Q1 2026; the contribution of organic flows beyond the deal close is the test of the franchise.
6. Statement-Based Combined RBC ratio drift. A drop below 350% or a NAIC-Based ratio below 370% signals capital being absorbed by loss recognition or assumption updates.
7. Mexico VAT and Asia FX/regulatory headlines. Watch for additional LatAm tax actions and Japan economic-value-based solvency disclosures that could drive one-time reserve or capital adjustments.